Loading clinical trials...

Dose Dense TC + Pegfilgrastim Support for Breast Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer

NCT01671319•University of Wisconsin, Madison

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the feasibility of giving standard TC chemotherapy on a dose dense schedule (ddTC) as well as evaluating the nature and frequency of ddTC side effects.

Detailed Description

A standard chemotherapy treatment option for breast cancer after surgery (adjuvant therapy) is docetaxel + cyclophosphamide (TC). This study looks at a different schedule for giving the same adjuvant chemotherapy so that treatment can be completed faster (in 8 weeks rather than 12 weeks). This study uses a growth factor drug, pegfilgrastim, to help build blood cells that are lowered because of chemotherapy, making it possible to receive TC treatment every 2 weeks (referred to as "dose dense TC" or "ddTC") instead of the standard 3 week schedule. The main study procedures are blood draws, chemotherapy treatment, physical exams, and pegfilgrastim injections.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•histologically confirmed invasive carcinoma of the female breast, status post definitive surgery (lumpectomy or mastectomy plus nodal evaluation if feasible). Patients must initiate therapy with ddTC within 84 days of the last breast or axillary surgery performed for curative intent
•candidate for chemotherapy by the treating oncologist
•Patients with pN2 or pN3 disease are NOT explicitly excluded. However, patients with N2 or N3 disease MUST be reviewed with the PI or study chair before being enrolled on the study as TC would not normally be considered adequate therapy for such patients.
•Patients with bilateral, synchronous invasive breast cancer are eligible as long as both primary tumors meet the eligibility criteria.
•Patients with estrogen-receptor (ER) and/or progesterone receptor (PR) negative, positive, or unknown tumors are eligible.
•Patients with HER2 positive, negative or unknown disease are eligible for this trial. Patients whose tumors are HER2 positive by either immunohistochemistry (IHC) 3+ staining or demonstrate gene amplification by FISH should receive trastuzumab, following completion of adjuvant cytotoxic therapy with 4 cycles of ddTC.
•There must be negative surgical margins for invasive cancer and DCIS. LCIS is acceptable at the margin.
•Patients with multi-centric breast cancer are eligible as long as all known disease is resected from the breast with negative margins.
•Age \>18 years.
•ECOG performance status ≤ 1
+9 more criteria

Exclusion Criteria

•Patient has received previous trastuzumab, chemotherapy, hormonal therapy, or other anti-cancer agents (including investigational agents) for this malignancy.
•Patient will be receiving GNRH agonists such as goserelin (Zoladex) or leuprolide acetate (Lupron) concomitantly with chemotherapy for the purpose of preventing breast cancer recurrence.
•Patient has inflammatory breast cancer (pT4d) or metastatic breast cancer.
•Patient has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements.
•Patient has pre-existing persistent neuropathy.
•The patient has received prior chemotherapy or radiotherapy or any malignancy within the past 2 years.
•Patient has received prior docetaxel or cyclophosphamide within the past 5 years.
•Patient has known contraindication or hypersensitivity to docetaxel, cyclophosphamide or pegfilgrastim.

Locations (1)

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, United States

Key Dates

Start Date

June 1, 2011

Primary Completion Date

April 1, 2013

Completion Date

April 1, 2013

Last Updated

November 27, 2019

Enrollment

ACTUAL participants

Conditions

Female Breast Cancer

Interventions

docetaxel + cyclophosphamide + pegfilgrastim

DRUG

PrefeRences And ChemoTherapy In Breast Cancer patiEnts

NCT06332976

Female Breast Cancer

View study

RECRUITINGNA

Pulsed Electromagnetic Fields for Analgesia Post Mastectomy

NCT06331793

Female Breast CancerPost Operative Pain

View study

NOT_YET_RECRUITINGPHASE2

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 27, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dose Dense TC + Pegfilgrastim Support for Breast Cancer

Inclusion Criteria

Exclusion Criteria

PrefeRences And ChemoTherapy In Breast Cancer patiEnts

Pulsed Electromagnetic Fields for Analgesia Post Mastectomy

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)

Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens

Breast Cancer in Young Women: Is it Different?